See more : ARIAKE JAPAN Co., Ltd. (2815.T) Income Statement Analysis – Financial Results
Complete financial analysis of Humanigen, Inc. (HGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humanigen, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- American Education Center, Inc. (AMCT) Income Statement Analysis – Financial Results
- Alpine 4 Holdings, Inc. (ALPP) Income Statement Analysis – Financial Results
- SunVic Technology Co., Ltd. (4304.TWO) Income Statement Analysis – Financial Results
- Besalco S.A. (BESALCO.SN) Income Statement Analysis – Financial Results
- Patel Engineering Limited (PATELENG.NS) Income Statement Analysis – Financial Results
Humanigen, Inc. (HGEN)
About Humanigen, Inc.
Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called 'cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is also being studied in conjunction with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1. Ifabotuzumab has been evaluated in a Phase 1 study of glioblastoma multiforme that showed tumor specific targeting of all known tumor sites with no normal tissue uptake. HGEN005 is being explored as a treatment for a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.51M | 3.60M | 312.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.00K | 6.10M | 20.26M | 17.71M | 589.00K |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 55.21M | 213.12M | 72.71M | 2.62M | 2.22M | 11.17M | 10.45M | 16.72M | 26.57M | 32.64M | 24.52M | 18.51M | 18.89M | 22.86M |
| General & Administrative | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.61M | 23.25M | 15.80M | 6.33M | 9.11M | 7.87M | 8.38M | 14.30M | 10.15M | 8.31M | 5.06M | 4.01M | 4.94M | 5.19M |
| Other Expenses | 0.00 | -1.61M | -1.00K | -1.00K | 324.00K | 431.00K | 125.00K | -213.00K | -154.00K | -39.00K | 113.00K | -8.00K | 915.00K | 348.00K |
| Operating Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Cost & Expenses | 70.82M | 236.37M | 88.51M | 8.94M | 11.33M | 19.03M | 18.83M | 31.02M | 36.72M | 40.95M | 29.58M | 22.52M | 23.84M | 28.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.00K | 88.00K | 86.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.92M | 2.26M | 1.34M | 1.35M | 852.00K | 3.06M | 131.00K | 842.00K | 1.21M | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 492.00K | -1.61M | -1.00K | -1.00K | 19.00K | 48.00K | 102.00K | 197.00K | 310.00K | 298.00K | 304.00K | 595.00K | 843.00K | 844.00K |
| EBITDA | -67.81M | -234.39M | -88.20M | -8.95M | -10.99M | -18.55M | -18.60M | -31.00M | -36.47M | -40.56M | -23.18M | -1.67M | -5.28M | -26.62M |
| EBITDA Ratio | -2,697.37% | -6,519.75% | -28,268.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,190.91% | -380.09% | -8.25% | -29.81% | -4,519.35% |
| Operating Income | -68.30M | -232.77M | -88.20M | -8.94M | -11.33M | -19.03M | -18.83M | -34.35M | -36.72M | -40.91M | -23.48M | -2.27M | -6.12M | -27.46M |
| Operating Income Ratio | -2,716.95% | -6,474.88% | -28,268.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -92,975.00% | -385.08% | -11.19% | -34.57% | -4,662.65% |
| Total Other Income/Expenses | -2.43M | -3.88M | -1.34M | -1.35M | -673.00K | -2.96M | -8.19M | -1.03M | -1.28M | -1.04M | -27.00K | 35.00K | 1.02M | 639.00K |
| Income Before Tax | -70.73M | -236.65M | -89.54M | -10.29M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.82M |
| Income Before Tax Ratio | -2,813.44% | -6,582.73% | -28,697.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,554.16% |
| Income Tax Expense | -492.00K | 2.26M | 1.34M | 1.35M | 179.00K | 3.49M | 256.00K | 629.00K | 1.06M | 1.05M | 140.00K | -43.00K | -108.00K | -19.00K |
| Net Income | -70.24M | -238.91M | -90.87M | -11.64M | -12.00M | -21.99M | -27.02M | -35.38M | -38.00M | -41.95M | -23.51M | -2.23M | -5.10M | -26.81M |
| Net Income Ratio | -2,793.87% | -6,645.70% | -29,125.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -95,336.36% | -385.52% | -11.02% | -28.79% | -4,550.93% |
| EPS | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| EPS Diluted | -1.18 | -4.08 | -2.46 | -0.52 | -0.63 | -7.34 | -13.92 | -42.88 | -46.09 | -69.13 | -448.66 | -46.17 | -97.33 | -85.16 |
| Weighted Avg Shares Out | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
| Weighted Avg Shares Out (Dil) | 59.49M | 58.53M | 36.96M | 22.36M | 18.95M | 3.00M | 1.94M | 825.00K | 824.48K | 606.76K | 52.40K | 48.34K | 52.40K | 314.77K |
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia
Humanigen Reports Third Quarter 2022 Financial Results
Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference
Humanigen Announces Retention of SC&H Capital as Financial Advisor
HGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 25, 2022 in the Class Action Filed on Behalf of Humanigen, Inc. Shareholders
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
HGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Humanigen, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
HGEN DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL Encourages Humanigen, Inc. Investors With Losses Exceeding $100K to Secure Counsel Before Important Tuesday Deadline in Securities Class Action - HGEN
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Humanigen Investors of a Lead Plaintiff Deadline of October 25, 2022
Humanigen Class Action: Levi & Korsinsky Reminds Humanigen, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 25, 2022 - HGEN
Source: https://incomestatements.info
Category: Stock Reports